or Try an Advanced Search...

    Treatment Of Cancer Stocks List

    Symbol Grade Name % Change
    MTEM F Molecular Templates, Inc. -2.06
    ONCT F Oncternal Therapeutics, Inc. 1.75
    EPIX F ESSA Pharma Inc. 1.73
    CATX F Perspective Therapeutics, Inc. -51.38
    AEMD F Aethlon Medical, Inc. -1.15
    CCM F Concord Medical Services Holdings Limited ADS 5.95
    HOWL F Werewolf Therapeutics, Inc. 8.54
    CCCC F C4 Therapeutics, Inc. -0.99
    LIXT F Lixte Biotechnology Holdings, Inc. 2.01
    AUTL F Autolus Therapeutics plc 1.43
    View As Page of Charts
    Related Industries: Biotechnology Diagnostics & Research Drug Manufacturers - Specialty & Generic Long-Term Care Facilities Medical Care Medical Instruments & Supplies Other Scientific & Technical Instruments
    Related Stock Lists: Cancer Biopharmaceutical Biotechnology Medicine Solid Tumors Cancer Treatment Clinical Development Life Sciences Lymphoma Medical Physics Radiation Therapy Sarcoma Ablation Advanced Prostate Cancer Advanced Solid Tumors Antiviral Drug Biology Biomarker Technology Biomarkers Brachytherapy

    Related ETFs - A few ETFs which own one or more of the above listed Treatment Of Cancer stocks.

    Symbol Grade Name Weight
    IDNA D iShares Genomics Immunology and Healthcare ETF 8.13
    FBT D First Trust Amex Biotech Index Fund 7.66
    PBE D PowerShares Dynamic Biotech & Genome 7.62
    CNCR F Loncar Cancer Immunotherapy ETF 6.82
    CANC D Tema Oncology ETF 4.08
    View all Treatment Of Cancer ETFs...
    Compare ETFs
    Compare CNCR to CANC Compare IDNA to CANC Compare PBE to CANC

        Treatment Of Cancer Stocks Recent News

        Date Stock Title
        Nov 21 CATX Perspective slips after Phase 1/2 trial data for radio pharma drug
        Nov 21 CATX Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium
        Nov 21 AUTL AUCATZYL's Approval Positions Autolus Therapeutics Favorably In The CAR-T Market
        Nov 20 HOWL Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference
        Nov 20 CCCC C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors
        Nov 19 AUTL Autolus Therapeutics upgraded to Buy from Neutral at Goldman Sachs
        Nov 16 CATX Is Perspective Therapeutics (CATX) the Best Multibagger Stock to Buy Heading into 2025?
        Nov 15 CATX Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024
        Nov 15 AUTL Autolus Therapeutics Third Quarter 2024 Earnings: US$0.31 loss per share (vs US$0.26 loss in 3Q 2023)
        Nov 15 AUTL Syncona Ltd (LSE:SYNC) Half Year 2025 Earnings Call Highlights: Navigating Market Challenges ...
        Related Industries: Biotechnology Diagnostics & Research Drug Manufacturers - Specialty & Generic Long-Term Care Facilities Medical Care Medical Instruments & Supplies Other Scientific & Technical Instruments
        Related Stock Lists: Cancer Biopharmaceutical Medicine Biotechnology Life Sciences Virotherapy Autoimmune Disease Clinical Development Clinical Medicine Immune Disorders Lymphoma Monoclonal Antibody Pharmaceutical Prostate Cancer Small Molecule Therapies Solid Tumors Tyrosine Kinase Achondroplasia Adoptive Cell Transfer Advanced Prostate Cancer
        Treatment Of Cancer

        Treatment of cancer depends on the type and stage of the cancer, as well as the patient's overall health and preferences. Treatment options may include surgery, radiation therapy, chemotherapy, immunotherapy, targeted therapy, and/or hormone therapy. In some cases, a combination of treatments may be used.

        Browse All Tags